



**HAL**  
open science

## Does missing data matter in the revised Patients' Attitude Towards Deprescribing questionnaire? A systematic review and two case analyses

Jérôme Nguyen-Soenen, Kristie Rebecca Weir, Katharina Tabea Jungo,  
Bastien Perrot, Jean-Pascal Fournier

### ► To cite this version:

Jérôme Nguyen-Soenen, Kristie Rebecca Weir, Katharina Tabea Jungo, Bastien Perrot, Jean-Pascal Fournier. Does missing data matter in the revised Patients' Attitude Towards Deprescribing questionnaire? A systematic review and two case analyses. *Research in Social and Administrative Pharmacy*, 2023, 20 (3), pp.296-307. 10.1016/j.sapharm.2023.12.010 . hal-04371587

**HAL Id: hal-04371587**

**<https://hal.science/hal-04371587>**

Submitted on 3 Jan 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

# **Does missing data matter in the revised Patients' Attitude Towards Deprescribing questionnaire? A systematic review and two case analyses**

Jérôme Nguyen-Soenen, MD, MSc<sup>1,2</sup>, Kristie Rebecca Weir, PhD<sup>3,4</sup>, Katharina Tabea Jungo<sup>3,5,6</sup>, PhD, Bastien Perrot, PhD<sup>1,7</sup>, Jean-Pascal Fournier, MD, PhD<sup>1,2</sup>

<sup>1</sup> SPHERE - UMR INSERM 1246, Université de Nantes, Université de Tours

<sup>2</sup> Département de Médecine Générale, Faculté de Médecine, Université de Nantes, France

<sup>3</sup> Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.

<sup>4</sup> Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.

<sup>5</sup> Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA

<sup>6</sup> Center for Healthcare Delivery Sciences (C4HDS), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA

<sup>7</sup> Direction de la recherche, Plateforme de Méthodologie et Biostatistique, CHU Nantes, Nantes, France.

**Corresponding author at:** Jerome Nguyen-Soenen, Department of General Practice, Faculty of Medicine, University of Nantes, France. Tel: 33 (0) 24 041 1129, Fax: 33 (0) 24 041 2879, e-mail: [jerome.nguyen-soenen@univ-nantes.fr](mailto:jerome.nguyen-soenen@univ-nantes.fr) ORCID: [0000-0002-9971-0672](https://orcid.org/0000-0002-9971-0672)

## **Abstract**

### **Background**

The revised Patients' Attitudes Towards Deprescribing (rPATD) questionnaire was developed to capture beliefs and perceptions of patients about deprescribing. In general, handling of missing data is underreported in survey studies. Underlying mechanisms related to missing data may impact the findings from survey studies.

### **Objectives**

The aim of this study was to assess the missing data in studies using the rPATD questionnaire through a systematic review and datasets from two studies.

### **Methods**

First, this review updated a systematic review on the rPATD (and other versions). We searched Medline via OVID, EMBASE, Scopus, Web of Science until 31<sup>st</sup> January 2023. Missing data reporting and methods to handle them were collected. Second, data from two deprescribing studies were analyzed using three methods of missing data handling: complete case analysis, personal mean substitution, and multiple imputation. We compared the scores from each domain and the associations of the domains with two questions from the rPATD to highlight how using different methods can influence the interpretation of study findings.

### **Results**

We identified 49 studies: 31 (63%) from this study and 18 (37%) from the original systematic review. The question or domain with the most missing data could be identified in 9 studies (18.4%). Missing data management was reported in 19 studies (38.8%). In one case analysis, the "Burden" domain was significantly associated with the question "*I would like to try stopping one of my medicines to see how I feel without it*" using complete case analysis

( $p=0.044$ ) or multiple imputation ( $p=0.038$ ), but not when using personal mean substitution ( $p=0.057$ ).

### **Conclusions**

Missing data and methods used to handle missing data were underreported in studies using the rPATD questionnaire. The methods should be chosen carefully as our analyses from two distinct studies suggest that they may impact the interpretation of the findings from the questionnaire.

**Keywords:** deprescribing; questionnaire; patient outcome assessment; missing data

**Abbreviations:** rPATD, revised-Patients' Attitude Toward Deprescribing

## 1. Introduction

Deprescribing is defined as “the process of withdrawal of an inappropriate medication, supervised by a health care professional with the goal of managing polypharmacy and improving outcomes”.<sup>1</sup> Deprescribing is a societal priority since polypharmacy and inappropriate medication use can result in significant side effects and drug interactions in an ageing population. Engaging patients in the deprescribing process and understanding their views is necessary to tailor intervention from a clinical or a research perspective. The revised Patients’ Attitudes Towards Deprescribing (rPATD) questionnaire was developed and validated in 2016.<sup>2</sup> It captures beliefs and perceptions of patients about deprescribing. To our knowledge, the rPATD is the most widely utilized questionnaire for measuring these outcomes. The rPATD fits the recommendations of minimum standards for patient-reported outcome measures in term of psychometric properties.<sup>3</sup>

Missing data is common in the field of patient-reported outcome measures and may lead to bias in the measure depending on the nature of the missing data if it is not considered. Missing data can be classified into three groups based on underlying reasons and mechanisms: missing completely at random, missing at random and missing not at random.<sup>4,5</sup> Missing completely at random occurs when missing data is unrelated to any study variable (*e.g.* broken pen making it impossible to fill in the boxes). Missing at random occurs when missing data is related to an observed variable (*e.g.* to explore a patient’s adherence to a medicine he/she does not have). Missing not at random occurs when missing data is related to the reason it is missing (*e.g.* drop-out of a clinical trial because the patient experiences side effects from the study drug).<sup>6</sup>

There are different ways to handle missing data in patient-reported outcome measures.<sup>7</sup> For instance, deletion methods such as complete case analysis removes all cases with at least one missing data. This method reduces the statistical power of analysis and may lead to selection bias if data are not missing completely at random.<sup>8</sup> Imputation of a missing value can be

performed using several methods. Personal mean score imputation substitutes the missing value with the mean of the other non-missing items of the subscale.<sup>9</sup> Multiple imputation replaces missing values with several options.<sup>4</sup> The appropriateness of these methods depends on the type and the proportion of missing data.<sup>10</sup>

In 2020, a systematic review and meta-analysis of the rPATD (and other versions) included 40 studies, however, the authors did not report the handling of missing data.<sup>11</sup> Several guidelines recommend how missing data and management should be addressed and reported, demonstrating the importance of selecting the most appropriate method.<sup>12,13</sup>

The aim of this study was to assess the handling of missing data in studies using the rPATD questionnaire through a systematic review and to assess the impact of missing data on rPATD results using datasets from two studies.

## **2. Methods**

This study included two steps. Firstly, we conducted a systematic review to describe the methods for handling missing data in studies that have used the rPATD questionnaire. Secondly, we showed how the methods for handling missing data can affect results using two examples from studies that previously used the rPATD questionnaire.

### 2.1 Systematic review

We followed the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) checklist.<sup>14</sup> This review updated a systematic review by Weir *et al.*<sup>11</sup>, following guidelines of the Cochrane handbook of systematic reviews.<sup>15</sup> While the previous systematic review included articles from 2016 to March 2020, we used the same search strategy to identify studies from March 2020 until 31<sup>st</sup> January 2023 (Appendix 1).

#### *2.1.1. Inclusion criteria*

Studies were eligible if they were original studies that included adults taking at least one medication. All study types and settings were included if the rPATD questionnaire or a translated version was used. No language or other exclusion criteria were applied. Duplicates were identified and excluded, and multiple reports of the same study were collated.

#### *2.1.2. Search*

We searched in Medline via OVID, EMBASE, Scopus, Web of Science from the end of the previous systematic review: 23 March 2020 to 31 January 2023. Two researchers (JNS and JPF) independently double screened the titles, abstracts and full texts. Any discrepancies were resolved by discussion. We added the results of this update to the included articles of the previous systematic review.

### *2.1.3. Outcomes*

We identified in each study the rate of missing data, the items or domains with the most missing data, and the methods used to handle missing data in the article or in supplementary files. The settings and who administered the questionnaire were also collected.

## 2.2. Cases analyses

### *2.2.1. Data source*

To study the impact of different methods to handle missing data, we performed two case analyses using data from two studies: the DeprescriPP trial and the LESS study. Both studies had used the rPATD to assess patients' attitudes towards deprescribing.

First, we used data from the DeprescriPP trial conducted in France, in which questionnaires containing the rPATD questions were sent to 2306 primary care patients aged  $\geq 65$  years who had been using proton pump inhibitors (PPI) for  $\geq 1$  year in November 2020. Participants were asked to return the completed questionnaires by postal mail. The DeprescriPP trial has not yet been published.<sup>16</sup>

Second, we used data from the Swiss LESS study in which questionnaires containing rPATD questions were administered to 306 patients aged  $\geq 70$  years, having  $\geq 3$  chronic conditions, and taking  $\geq 5$  chronic medications, after these patients had been recruited by their general practitioners. Questionnaires were completed in the general practitioner's waiting room or at home from May 2018 to February 2019. The LESS Study has already been published.<sup>17</sup>

### *2.2.2. Assessment of patients' attitudes towards deprescribing*

The rPATD contains 22 items: 20 questions covering four domains (five items for each domain): i) belief in appropriateness of the medication use ("Appropriateness"), ii) perceived



burden of medication taking (“Burden”), iii) concerns about stopping (“Concerns about stopping”), and iv) level of involvement in medication management (“Involvement”), and two global questions “Overall, I am satisfied with my current medicines” and “If my doctor said it was possible, I would be willing to stop one or more of my regular medicines” (Appendix 2). Each item in the burden, concerns about stopping and involvement domains is noted on a 5-point Likert scale from 1 to 5 (“strongly disagree” to “strongly agree”). Items from the appropriateness domain were reverse scored because of negatively worded items.<sup>2</sup> Domain scores were calculated with the mean of the five items. Higher scores in each domain indicated a greater perceived burden, appropriateness, concerns about stopping and involvement in medication management.

### 2.2.3. Statistical analysis

We applied an algorithm developed by Mirzaei *et al.* to provide a guidance on possible methods for handling missing data.<sup>7</sup> We evaluated the missing data in the two datasets from the DeprescriPP and LESS studies. The algorithm considers the missing data as negligible if they represent less than 5% of the dataset. Performing a Little’s Test of Missingness is recommended if missing data occurred between 5 and 40% to determine whether the data could be classified as missing completely at random. A significant p-value <0.05 means that the data are not missing completely at random.<sup>18</sup> Then, data can be classified as missing at random if an observed variable is structurally related to the missing data. Otherwise, data is classified as missing not at random. We described the mean score at the domain-level using three different methods: pair-wise deletion, personal mean score imputation, and multiple imputation (mi-two way, as described by Van Ginkel *et al.*).<sup>19</sup> To illustrate the impact of the three different methods, we dichotomized the global question “If my doctor said it was possible, I would be willing to stop one or more of my regular medicines” in a binary outcome with agree for those

who responded agree or strongly agree and disagree for those who responded disagree for those who responded strongly disagree, disagree or unsure. We performed a multiple logistic regression to analyze the association between the global question and the four domains to compare the three different methods. A sensitivity analysis was performed using the question “*I would like to try stopping one of my medicines to see how I feel without it*” (item 2 of the Appropriateness domain). This question has been used in previous studies for sensitivity analyses and as the primary outcome because it may capture the patient's willingness to deprescribe separately from the influence of the doctor and seems less susceptible to the ceiling effect.<sup>20,21</sup> We dichotomized this question in a binary outcome with agree for those who responded strongly agree, agree or unsure and disagree for those who responded strongly disagree or disagree. We performed a multiple logistic regression to analyze the association between this specific item and the four domains to compare the three different methods. We calculated odd ratios (OR) and 95% confidence interval. A p-value <0.05 was considered statistically significant. Microsoft Excel 2019 (Microsoft Corporation) was used for data management and statistical analysis were performed using Stata 17.0 (StataCorp, College Station, TX, USA).

#### *2.2.4. Ethics approval*

The DeprescriPP trial has been approved by the Ethics Committee of the *Collège National des Généralistes Enseignants* (#08062011).<sup>16</sup> Ethical approval for the LESS study was obtained from the Ethics Committee of the Canton of Bern, Switzerland (Ref. 2017–02188).<sup>17</sup>

### **3. Results**

#### *3.1. Systematic review*

We identified 49 studies: 18 (36.7%) from the original systematic review and 31 (63.3%) from the present update (Figure 1). The design, methods, number of participating patients, and other characteristics of included studies are presented in Table 1. Sample sizes ranged from 18 to 1981 participants with a total of 14,898 participants. Study designs were the following: cross-sectional surveys (32, 65.3%), surveys nested in a longitudinal study (10, 20.4%) and development, validation, and cross-cultural adaptation studies (7, 14.3%). How the questionnaire was administered was described in 38 studies (77.6%) including self-administered (n=16, 42.1%), researcher-administered (n=15, 39.5%), self-administered with help available (n=7, 18.4%).

Missing data management was reported in 19 studies (38.8%). The methods used for handling missing data were complete case analysis (n=12, 63.2%), pair-wise deletion (*i.e.*, analysis when data of interest was available, n=3, 15.8%), other methods (n=4, 21.1%: two studies excluded questionnaires from the analysis if more than 50% of items were missing and two excluded the domain if at least 40% of items were missing).

The methods used for handling missing data were reported in seven studies (43.8%) when the rPATD was self-administered. For the other administration mode, methods were reported in six studies (27.3%). In nine studies (18.4%), the question or domain with the most missing data could be identified. Namely, the question “I spend a lot of money on my medicine” (n=4, 44.4%) and the “Burden” domain (n=3, 33.3%) were most often reported missing.

#### *3.2 Case analyses*

##### *3.2.1. Results from the DeprescriPP dataset (France)<sup>16</sup>*

In total, 1151 (49.9%) questionnaires were received. There were 769 (66.8%) complete rPATD questionnaires. The item with the lowest percentage of missing data was “I think one or more of my medicines may not be working” (91, 7.9%) and the domain with the lowest percentage of missing data was “Involvement” (173, 15.0%). The item with the highest percentage of missing data was “I have had a bad experience when stopping a medicine before” (170, 14.8%) and the most incomplete domain (i.e., with at least one missing item) was “Concerns about stopping” (232, 20.2%). Data were not classified as missing completely at random given Little’s Test of Missingness was significant ( $p=0.019$ ). Missing were classified as missing not at random, as unrelated to another observed variable. The scores of each domain appeared similar regardless of deletion methods or substitution methods (Table 2).

High level of agreement in the “Involvement” and low levels in the “Appropriateness” and “Concerns about stopping” domain were significantly associated with agreement to the global question “If my doctor said it was possible, I would be willing to stop one or more of my regular medicines”, with the same strengths of association, irrespective of the three methods used to handle missing data (Table 3). Regarding the sensitivity analysis, the four domains were significantly associated with the question “I would like to try stopping one of my medicines to see how I feel without it”, irrespective of the three methods used to handle missing data (Table 4).

### *3.2.2. Results from the LESS dataset (Switzerland)<sup>17</sup>*

In total, 306 rPATD questionnaires were completed by participants. There were 268 (87.6%) complete questionnaires. The items with the lowest percentage of missing data were “I have a good understanding of the reasons I was prescribed each of my medicines” and “Overall, I am satisfied with my current medicines” (1, 0.3%) and the domain with the lowest percentage of missing data was “Appropriateness” (9, 2.9%). The items with the highest percentage of

missing data were “I spend a lot of money on my medicines” (8, 2.6%), “I would be reluctant to stop a medicine that I had been taking for a long time” (8, 2.6%), and “I have had a bad experience when stopping a medicine before” (8, 2.6%) and the most incomplete domain was “Concerns about stopping” (17, 5.6%). Following the algorithm from Mirzaei *et al.* <sup>7</sup>, missing data were considered negligible. The scores of each domain appeared similar regardless of deletion methods or substitution methods (Table 5).

Low levels of agreement in the “Appropriateness” and “Concerns about stopping” domains were significantly associated with the global question “If my doctor said it was possible, I would be willing to stop one or more of my regular medicines”, with the same strength of association, irrespective of the three methods used to handle missing data (Table 6).

Regarding the sensitivity analysis, the domains “Appropriateness” and “Involvement” were significantly associated with the question “I would like to try stopping one of my medicines to see how I feel without it”, irrespective of the three methods used to handle missing data (Table 7). The domain “Burden” was significantly associated with this question by using complete case analysis ( $p=0.044$ ) or multiple imputation ( $p=0.038$ ), but not by using personal mean substitution ( $p=0.057$ ).

#### 4. Discussion

The rPATD has been used in 49 studies since its development and validation in 2016, with a two-fold increase in the past three years alone. Missing data and methods for handling them were rarely reported. Our case analyses revealed that methods for handling missing data had a significant impact on rPATD findings, although it was not major.

Despite the existence of guidelines for reporting survey studies, researchers often overlook reporting how they have dealt with missing data, and lack consideration for the implications of handling missing data in their analyses.<sup>12,22</sup> Our systematic review suggest that the same can be said for researchers using the rPATD, since only four out of ten reported how they managed missing data. Our findings suggest that this may relate to the study design and how the questionnaire was administered. Less than half of the studies included in our systematic review self-administered the rPATD, although it was designed this way,<sup>2</sup> and the remaining studies were administered by a researcher or with help available. We found that methods for handling missing data were more often reported when the rPATD was self-administered. A researcher or clinician administering the questionnaire may reduce the amount of missing data but may influence the interpretation of items. It may also lead to social desirability bias with participants reporting more desirable attitudes and less undesirable ones.<sup>23</sup>

Complete case analysis was the most common method to handle missing data. Similarly, a systematic review of questionnaires by Eekhout *et al.* in 2010 found complete case analysis to be the most common method used in 262 studies published in epidemiology journals.<sup>24</sup> However, complete case analysis can only be used when data is missing completely at random to avoid bias.<sup>25</sup> Also, complete case analysis can lead to a reduction in the sample size and a loss of power depending on the level of missingness.

In our case analyses, the different methods for handling missing data did not significantly modify the findings of the primary analysis. For the DeprescriPP study, this can be explained

by having a sample large enough to maintain sufficient statistical power. For the LESS study, there were few missing data which may have been due to recruitment strategy by general practitioners and the fact that the questionnaire could potentially have been administered in the waiting room (*versus* postal survey for the DeprescriPP trial).<sup>17</sup> However, the sensitivity analysis highlighted a minor difference between the three methods for handling missing data in the LESS study. The item “*I would like to try stopping one of my medicines to see how I feel without it*” was significantly associated with the domain “Burden” using complete case analysis and multiple imputation methods but not with person mean substitution method. This illustrated that methods for handling missing data may impact findings in some scenarios and thus, should be reported carefully.

This study comes with several limitations. First, we conveniently selected two deprescribing studies for our case analyses because the co-authors had access to the data. Nevertheless, these data permitted to perform secondary analyses, which adequately showed the effects of different methods used for handling missing data.

Second, we chose to perform our analyses on original data from two questionnaire studies. These two studies permitted to evaluate missing data in the questionnaire under different study designs, settings and administration modes. However, our findings may not be generalizable beyond the primary care setting, and we excluded the following administration modes: online or researcher-administered. A simulation study with several scenarios of missingness rates may be needed to further explore the differences between the methods of missing data for the rPATD questionnaire, similarly to a previous study on quality of life questionnaires.<sup>26</sup>

## **Conclusions**

In this study, we conducted a focused update of the systematic review on studies using the rPATD questionnaire. Additionally, we explored different methods to handle missing data using datasets from two distinct studies to assess their impact on their results. Our findings suggest that administration modes of questionnaire, missing data and methods used to handle missing data should be systematically reported to improve the quality of survey studies, as they may affect rPATD survey results. In some scenarios, the methods used to handle missing data may have an impact on the interpretation of the results on patients' willingness to have medications deprescribed.



## **Registration and protocol**

The update of this systematic review was not registered. The protocol of the original systematic review was registered in PROSPERO (CRD42020150007).

## **Ethics**

The DeprescriPP trial has been approved by the Ethics Committee of the Collège National des Généralistes Enseignants (#08062011). Ethical approval for the LESS study was obtained from the Ethics Committee of the Canton of Bern, Switzerland (Ref. 2017–02188).

## **Funding**

This study was not funded. The DeprescriPP trial was supported by a grant from the French Ministry of Health (PREPS 2019). The LESS study was supported by a grant from the Swiss Society of General Internal Medicine. Dr Weir was funded by an Emerging Leader Research Fellowship (2017295) from the Australian National Health and Medical Research Council. Dr Jungo was supported by a Postdoc. Mobility Fellowship from the Swiss National Science Foundation (P500PM\_206728).

## **Competing interests**

The authors declare that they have no competing interests.

## **Acknowledgements**

The authors would like to thank Prof. Sven Streit for sharing the rPATD questionnaire database of the LESS Study.

## **Availability of data and materials**

Data and materials are available upon request of the corresponding author.

## 5. References

1. Reeve E, Gnjjidic D, Long J, Hilmer S. A systematic review of the emerging definition of ‘deprescribing’ with network analysis: implications for future research and clinical practice. *Br J Clin Pharmacol*. 2015;80(6):1254-1268. doi:10.1111/bcp.12732
2. Reeve E, Low LF, Shakib S, Hilmer SN. Development and Validation of the Revised Patients’ Attitudes Towards Deprescribing (rPATD) Questionnaire: Versions for Older Adults and Caregivers. *Drugs Aging*. 2016;33(12):913-928.
3. Reeve BB, Wyrwich KW, Wu AW, et al. ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. *Qual Life Res*. 2013;22(8):1889-1905. doi:10.1007/s11136-012-0344-y
4. Little RJ, Rubin DB. *Statistical Analysis with Missing Data*. Vol 793. John Wiley & Sons; 2019.
5. Rubin DB. Inference and missing data. *Biometrika*. 1976;63(3):581-592. doi:10.1093/biomet/63.3.581
6. Mack C, Su Z, Westreich D. Types of Missing Data. In: *Managing Missing Data in Patient Registries: Addendum to Registries for Evaluating Patient Outcomes: A User’s Guide, Third Edition [Internet]*. Agency for Healthcare Research and Quality (US); 2018. Accessed September 12, 2023. <https://www.ncbi.nlm.nih.gov/books/NBK493614/>
7. Mirzaei A, Carter SR, Patanwala AE, Schneider CR. Missing data in surveys: Key concepts, approaches, and applications. *Res Soc Adm Pharm*. 2022;18(2):2308-2316. doi:10.1016/j.sapharm.2021.03.009

8. Jamshidian M, Mata M. 2 - Advances in Analysis of Mean and Covariance Structure when Data are Incomplete. In: Lee SY, ed. *Handbook of Latent Variable and Related Models*. Handbook of Computing and Statistics with Applications. North-Holland; 2007:21-44. doi:10.1016/B978-044452044-9/50005-7
9. Morris J, Coyle D. Quality of life questionnaires in cancer clinical trials: Imputing missing values. *Psychooncology*. 1994;3(3):215-222. doi:10.1002/pon.2960030308
10. Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should multiple imputation be used for handling missing data in randomised clinical trials – a practical guide with flowcharts. *BMC Med Res Methodol*. 2017;17(1):162. doi:10.1186/s12874-017-0442-1
11. Weir KR, Ailabouni NJ, Schneider CR, Hilmer SN, Reeve E. Consumer Attitudes Towards Deprescribing: A Systematic Review and Meta-Analysis. *J Gerontol A Biol Sci Med Sci*. 2022;77(5):1020-1034. doi:10.1093/gerona/glab222
12. Sharma A, Minh Duc NT, Luu Lam Thang T, et al. A Consensus-Based Checklist for Reporting of Survey Studies (CROSS). *J Gen Intern Med*. 2021;36(10):3179-3187. doi:10.1007/s11606-021-06737-1
13. Calvert M, Kyte D, Mercieca-Bebber R, et al. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. *JAMA*. 2018;319(5):483-494. doi:10.1001/jama.2017.21903
14. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. doi:10.1136/bmj.n71
15. Cumpston M, Chandler J. Chapter IV: Updating a review. In: *Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (Editors). Cochrane Handbook for*

*Systematic Reviews of Interventions Version 6.3 (Updated February 2022)*. Cochrane, 2022. Accessed February 23, 2023. <https://training.cochrane.org/handbook>

16. Nguyen-Soenen J, Rat C, Gaultier A, Schirr-Bonnans S, Tessier P, Fournier JP. Effectiveness of a multi-faceted intervention to deprescribe proton pump inhibitors in primary care: protocol for a population-based, pragmatic, cluster-randomized controlled trial. *BMC Health Serv Res*. 2022;22(1):219. doi:10.1186/s12913-022-07496-3
17. Rozsnyai Z, Jungo KT, Reeve E, et al. What do older adults with multimorbidity and polypharmacy think about deprescribing? The LESS study - a primary care-based survey. *BMC Geriatr*. 2020;20(1):435. doi:10.1186/s12877-020-01843-x
18. Little RJA. A Test of Missing Completely at Random for Multivariate Data with Missing Values. *J Am Stat Assoc*. 1988;83(404):1198-1202. doi:10.1080/01621459.1988.10478722
19. Van Ginkel JR, Van Der Ark LA, Sijtsma K. Multiple Imputation of Item Scores in Test and Questionnaire Data, and Influence on Psychometric Results. *Multivar Behav Res*. 2007;42(2):387-414. doi:10.1080/00273170701360803
20. Scott S, Clark A, Farrow C, et al. Attitudinal predictors of older peoples' and caregivers' desire to deprescribe in hospital. *BMC Geriatr*. 2019;19(1):108. doi:10.1186/s12877-019-1127-x
21. McCarthy C, Flood M, Clyne B, et al. Association between patient attitudes towards deprescribing and subsequent prescription changes. *Basic Clin Pharmacol Toxicol*. 2023;n/a(n/a). doi:10.1111/bcpt.13859
22. Rombach I, Rivero-Arias O, Gray AM, Jenkinson C, Burke Ó. The current practice of handling and reporting missing outcome data in eight widely used PROMs in RCT

- publications: a review of the current literature. *Qual Life Res.* 2016;25(7):1613-1623.  
doi:10.1007/s11136-015-1206-1
23. Bowling A. Mode of questionnaire administration can have serious effects on data quality. *J Public Health Oxf Engl.* 2005;27(3):281-291. doi:10.1093/pubmed/fdi031
24. Eekhout I, de Boer MR, Twisk JWR, de Vet HCW, Heymans MW. Brief Report: Missing Data: A Systematic Review of How They Are Reported and Handled. *Epidemiology.* 2012;23(5):729-732.
25. Altman DG, Bland JM. Missing data. *BMJ.* 2007;334(7590):424-424.  
doi:10.1136/bmj.38977.682025.2C
26. Peyre H, Leplège A, Coste J. Missing data methods for dealing with missing items in quality of life questionnaires. A comparison by simulation of personal mean score, full information maximum likelihood, multiple imputation, and hot deck techniques applied to the SF-36 in the French 2003 decennial health survey. *Qual Life Res.* 2011;20(2):287-300.  
doi:10.1007/s11136-010-9740-3
27. Achterhof AB, Rozsnyai Z, Reeve E, et al. Potentially inappropriate medication and attitudes of older adults towards deprescribing. *PLOS ONE.* 2020;15(10):e0240463.  
doi:10.1371/journal.pone.0240463
28. Alshammari S, Albarrak R, Alajmi A, Alsomali N, Alaqil A, Alenezy N. Patients' attitude towards deprescribing among elderly inpatients with polypharmacy at tertiary academic hospital: A cross-sectional study. *Med Sci.* 2021;25(116):2512-2523 WE-Emerging Sources Citation Index (ESCI).

29. Bucsa C, Onea M, Rusu A, et al. Patients' Attitudes Towards Deprescribing-A Cross-sectional Study in Older Patients in Romania. *Drug Saf.* 2022;45(10):1270-1271. doi:10.1007/s40264-022-01219-7
30. Bužančić I, Dragović P, Pejaković TI, Markulin L, Ortner-Hadžiabdić M. Exploring patients' attitudes toward deprescribing and their perception of pharmacist involvement in a european country: A cross-sectional study. *Patient Prefer Adherence.* 2021;15:2197-2208. doi:10.2147/PPA.S323846
31. Cardwell K, Smith SM, Clyne B, et al. Evaluation of the General Practice Pharmacist (GPP) intervention to optimise prescribing in Irish primary care: a non-randomised pilot study. *BMJ Open.* 2020;10(6):e035087. doi:10.1136/bmjopen-2019-035087
32. Cardwell K, Smith SM, Clyne B. Evaluation of the General Practice Pharmacist (GPP) intervention to optimise prescribing in Irish primary care: a non-randomised pilot study. *BMJ Open.* 2020;10(6).
33. Cateau D, Foley RA, Niquille A. Déprescrire en EMS : regards croisés entre les résidents, leurs proches et les professionnels de santé.
34. de Juan-Roldán JI, Castillo-Jimena M, González-Hevilla A, Sánchez-Sánchez C, García-Ruiz AJ, Gavilán-Moral E. Cross-cultural adaptation and psychometric validation of a Spanish version of the revised Patients' Attitudes Towards Deprescribing (rPATD) questionnaire. *BMJ Open.* 2022;12(4):e050678. doi:10.1136/bmjopen-2021-050678
35. Edelman M, Jellema P, Hak E, Denig P, Blanker MH. Patients' Attitudes Towards Deprescribing Alpha-Blockers and Their Willingness to Participate in a Discontinuation Trial. *Drugs Aging.* 2019;36(12):1133-1139. doi:10.1007/s40266-019-00712-6

36. Edelman M, Blanker M, Jellema P, Hak E, Denig P. Patient attitudes towards deprescribing of alpha-blockers and willingness to participate in a discontinuation trial. *Neurol Urodyn*. 2017;36(Supplement 3).
37. Gaurang N, Priyadharsini R, Balamurugesan K, Prakash M, Reka D. Attitudes and beliefs of patients and primary caregivers towards deprescribing in a tertiary health care facility. *Pharm Pract*. 2021;19(3):2350. doi:<https://dx.doi.org/10.18549/PharmPract.2021.3.2350>
38. Gilpin R, McDade OC, Edwards C. Attitudes toward deprescribing for hospital inpatients. *Clin Med*. 2022;22(1):58.
39. Gnjidic D, Ong HMM, Leung C, Jansen J, Reeve E. The impact of in hospital patient-education intervention on older people's attitudes and intention to have their benzodiazepines deprescribed: a feasibility study. *Ther Adv Drug Saf*. 2019;10.
40. Growdon ME, Espejo E, Jing B, et al. Attitudes toward deprescribing among older adults with dementia in the United States. *J Am Geriatr Soc*. n/a(n/a). doi:10.1111/jgs.17730
41. Hanna V, Chahine B, Souheil FA. Attitudes of Lebanese community-dwelling older adults towards deprescribing using the rPATD tool. *Arch Gerontol Geriatr*. 2023;105:104840. doi:10.1016/j.archger.2022.104840
42. Ikeji C, Williams A, Hennawi G, Brandt NJ. Patient and Provider Perspectives on Deprescribing Proton Pump Inhibitors. *J Gerontol Nurs*. 2019;45(10):9-17. doi:10.3928/00989134-20190912-03
43. Ikeji CA, Brandt N, Hennawi G, Williams A. Patient and prescriber perspectives on proton pump inhibitor (PPI) use and deprescribing in older adults. *J Am Geriatr Soc*. 2019;67(Supplement 1).



44. Jungo KT, Meier R, Valeri F, et al. Baseline characteristics and comparability of older multimorbid patients with polypharmacy and general practitioners participating in a randomized controlled primary care trial. *BMC Fam Pract.* 2021;22(1):123. doi:10.1186/s12875-021-01488-8
45. Jungo KT, Meier R, Valeri F, et al. Baseline characteristics and external validity of older multimorbid patients with polypharmacy and general practitioners enrolled in a randomized controlled primary care trial. *Eur J Gen Pr.* 2021;27(1):361. doi:10.1080/13814788.2021.2008352
46. Kua CH, Reeve E, Ratnasingam V, Mak VSL, Lee SWH. Patients' and Caregivers' Attitudes Towards Deprescribing in Singapore. *J Gerontol Ser A.* Published online January 22, 2020;glaa018. doi:10.1093/gerona/glaa018
47. Kua KP, Saw PS, Lee SWH. Attitudes towards deprescribing among multi-ethnic community-dwelling older patients and caregivers in Malaysia: a cross-sectional questionnaire study. *Comment Int J Clin Pharm.* 2019;41(5):1131-1132.
48. Kua KP, Saw PS, Lee SWH. Attitudes towards deprescribing among multi-ethnic community-dwelling older patients and caregivers in Malaysia: a cross-sectional questionnaire study. *Int J Clin Pharm.* 2019;41(3):793-803.
49. Khasawneh RA, Nusair MB, Arabyat RM, Karasneh R, Al-Azzam S. The Association Between e-Health Literacy and Willingness to Deprescribe Among Patients with Chronic Diseases: A Cross-Sectional Study from Jordan. *Telemed E-Health.* 2022;28(7):1001-1008. doi:10.1089/tmj.2021.0331

50. Lee HG, Kwon S, Jang BH, et al. A Study on the Perceptions of Korean Older Adult Patients and Caregivers about Polypharmacy and Deprescribing. *Int J Environ Res Public Health*. 2022;19(18):11446.
51. Lukacena KM, Keck JW, Freeman PR, Harrington NG, Huffmyer MJ, Moga DC. Patients' attitudes toward deprescribing and their experiences communicating with clinicians and pharmacists. *Ther Adv Drug Saf*. 2022;13. doi:10.1177/20420986221116465
52. Lundby C, Glans P, Simonsen T, et al. Attitudes towards deprescribing: The perspectives of geriatric patients and nursing home residents. *J Am Geriatr Soc*. 2021;69(6):1508-1518. doi:10.1111/jgs.17054
53. Lundby C, Simonsen T, Ryg J, Sondergaard J, Pottegard A, Lauridsen HH. Translation, cultural adaptation, and psychometric properties of the Danish version of the revised Patients' attitudes towards Deprescribing questionnaire. *Pharmacoepidemiol Drug Saf*. 2019;28(Supplement 2):291-292.
54. Lundby C, Simonsen T, Ryg J, Sondergaard J, Pottegard A, Lauridsen HH. Translation, cross-cultural adaptation, and psychometric properties of the danish version of the revised patients' attitudes towards deprescribing questionnaire. *Pharmacoepidemiol Drug Saf*. 2020;29:402-403. doi:10.1002/pds.5114
55. Major GL, Mills A, Lowthian JA. Deprescribing Attitudes of Older Adults Receiving Medication Management Support From Home-Based Nurses. *J Am Geriatr Soc*. 2019;67(8):1756-1757.
56. Martinez AI, Spencer J, Moloney M, Badour C, Reeve E, Moga DC. Attitudes toward deprescribing in a middle-aged health disparities population. *Res Soc Adm Pharm*. Published online March 10, 2020. doi:10.1016/j.sapharm.2020.02.014

57. McCarthy C, Clyne B, Bol, et al. GP-delivered medication review of polypharmacy, deprescribing, and patient priorities in older people with multimorbidity in Irish primary care (SPPiRE Study): A cluster randomised controlled trial. *PLoS Med.* 2022;19(1):e1003862.
58. Navid P, Nguyen L, Jaber D, et al. Attitudes toward deprescribing among adults with heart failure with preserved ejection fraction. *J Am Geriatr Soc.* 2021;69(7):1948-1955. doi:10.1111/jgs.17204
59. Ng KY, Lee SWH. Attitude of older patients with Parkinson's disease towards deprescribing: A pilot study. *J Park Dis.* 2019;9(1).
60. Nusair MB, Arabyat RM, Arabyat RM, et al. Translation and psychometric properties of the Arabic version of the revised Patients' Attitudes Towards Deprescribing questionnaire. *J Pharm Health Serv Res.* Published online 2020. doi:10.1111/jphs.12340
61. Nusair M, Khasawneh R, Al-azzam S, Al-Shuqairat T, Khair Z, Arabyat R. Attitudes towards adherence and deprescribing among polypharmacy patients: a cross-sectional study. *J Pharm Health Serv Res.* 2022;13(3):180-190. doi:10.1093/jphsr/rmac028
62. Oktora MP, Yuniar CT, Amalia L, Abdulah R, Hak E, Denig P. Attitudes towards deprescribing and patient-related factors associated with willingness to stop medication among older patients with type 2 diabetes (T2D) in Indonesia: a cross-sectional survey study. *BMC Geriatr.* 2023;23(1):21. doi:10.1186/s12877-022-03718-9
63. Omar MS, Ariandi AH, Tohit NM. Practical problems of medication use in the elderly Malaysians and their beliefs and attitudes toward deprescribing of medications. *J Res Pharm Pract.* 2019;8(3).

64. Paque K. Balancing medication use in nursing home residents with life-limiting disease. *Eur J Clin Pharmacol*. Published online 2019.
65. Pereira A, Ribeiro O, Veriíssimo M. Portuguese older patients' attitudes toward deprescribing. *Eur Geriatr Med*. 2020;11:S272. doi:10.1007/s41999-020-00428-6
66. Pereira A, Ribeiro O, Verissimo M. Chronic medical conditions and willingness to deprescribe in older adults. *Eur Geriatr Med*. 2022;13:S423. doi:10.1007/s41999-022-00711-8
67. Pereira A, Ribeiro O, Verissimo M. Willingness to deprescribe in community-dwelling older adults: The importance of age, sex, and having concerns about stopping medicines. *Eur Geriatr Med*. 2022;13:S424. doi:10.1007/s41999-022-00711-8
68. Pereira A, Ribeiro O, Verissimo M. Polypharmacy and patients' willingness to deprescribe: A study with community-dwelling older adults. *Eur Geriatr Med*. 2022;13:S424-S425. doi:10.1007/s41999-022-00711-8
69. Pereira A, Ribeiro O, Veriíssimo M. Translation, cross-cultural adaptation and validation of the revised Patients' Attitudes Towards Deprescribing (rPATD) questionnaire to Portuguese: Older adults version. *Res Soc Adm Pharm*. Published online September 5, 2022. doi:10.1016/j.sapharm.2022.08.015
70. Rakheja B, Sirois C, Ouellet N, Roux B, Laroche ML. Attitudes Toward Deprescribing in Older Adults and Caregivers: A Survey in Quebec, Canada. *J Appl Gerontol*. Published online March 4, 2022:07334648211069553. doi:10.1177/07334648211069553
71. Reeve E, Anthony AC, Kouladjian O'Donnell L, et al. Development and pilot testing of the revised Patients' Attitudes Towards Deprescribing questionnaire for people with

- cognitive impairment. *Australas J Ageing*. 2018;37(4):E150-E154.  
doi:10.1111/ajag.12576
72. Reeve E, Low LF, Hilmer SN. Attitudes of Older Adults and Caregivers in Australia toward Deprescribing. *J Am Geriatr Soc*. 2019;67(6):1204-1210. doi:10.1111/jgs.15804
73. Reeve E, Low LF, Shakib S, Hilmer SN. Development and Validation of the Revised Patients' Attitudes Towards Deprescribing (rPATD) Questionnaire: Versions for Older Adults and Caregivers. *Drugs Aging*. 2016;33(12):913-928. doi:10.1007/s40266-016-0410-1
74. Reeve E, Wolff JL, Skehan M, Bayliss EA, Hilmer SN, Boyd CM. Assessment of Attitudes Toward Deprescribing in Older Medicare Beneficiaries in the United States. *JAMA Intern Med*. Published online 2018. doi:10.1001/jamainternmed.2018.4720
75. Reeve E, Bayliss EA, Shetterly S, et al. Willingness of older people living with dementia and mild cognitive impairment and their caregivers to have medications deprescribed. *Age Ageing*. 2023;52(1). doi:https://dx.doi.org/10.1093/ageing/afac335
76. Maiyani M, Reeve E, Bayliss E, Shetterly S, Gleason K, Boyd C. HSD18 High Willingness to Deprescribe Among People Living with Dementia and Mild Cognitive Impairment. *Value Health*. 2022;25(7):S483. doi:10.1016/j.jval.2022.04.1020
77. Roux B, Rakheja B, Sirois C, et al. Attitudes and beliefs of older adults and caregivers towards deprescribing in French-speaking countries: a multicenter cross-sectional study. *Eur J Clin Pharmacol*. 2022;78(10):1633-1646. doi:10.1007/s00228-022-03368-1

78. Roux B, Sirois C, Niquille A, et al. Cross-cultural adaptation and psychometric validation of the revised Patients' Attitudes Towards Deprescribing (rPATD) questionnaire in French. *Res Soc Adm Pharm.* 2021;17(8):1453-1462. doi:10.1016/j.sapharm.2020.11.004
79. Saka S, Odueke D, Odusan O, Oyinloye O, Okunye O. The Attitude of Older Patients to Deprescribing Polypharmacy in Ogun State, Nigeria. *Ann Health Res.* 2022;8(4):305-314.
80. Serrano Giménez R, Gallardo Anciano J, Robustillo Cortés MA, et al. Identificación de creencias y actitudes relacionadas con la deprescripción en pacientes VIH+ de edad avanzada: Proyecto ICARD. *Rev Esp Quimioter.* 2021;34(1):18-27. doi:10.37201/req/084.2020
81. Shrestha S, Poudel A, Reeve E, Linsky AM, Steadman KJ, Nissen LM. Development and validation of a tool to understand health care professionals' attitudes towards deprescribing (HATD) in older adults with limited life expectancy. *Res Soc Adm Pharm RSAP.* Published online March 8, 2022:S1551-7411(22)00057-2. doi:10.1016/j.sapharm.2022.03.002
82. Tan J, Wang M, Pei X, et al. Continue or not to continue? Attitudes towards deprescribing among community-dwelling older adults in China. *BMC Geriatr.* 2022;22(1):492. doi:10.1186/s12877-022-03184-3
83. Tegegn HG, Tefera YG, Erku DA. Older patients' perception of deprescribing in resource-limited settings: A cross-sectional study in an Ethiopia university hospital. *BMJ Open.* 2018;8(4).

## 6. Figures




Figure 1: PRISMA flow-chart diagram for the updated systematic review

rPATD: revised Patients' Attitudes Towards Deprescribing

## 7. Tables

**Table 1.** Study characteristics, questionnaire administration and missing data handling

Source Year Country	Sample size, Study design	Study population	Questionnaire administration, Setting	Translated Language	Questionnaire modification how	Reporting of missing data management	Item/domain with the highest missing data (proportion)*
Achterhof <i>et al.</i> , 2020, Switzerland <sup>27</sup>  Rozsnyai <i>et al.</i> 2020, Switzerland <sup>17</sup>	306, cross-sectional survey	Primary care patients ≥ 70 years, ≥ 3 chronic diseases, ≥ 5 long-term medications	Anonymously self-reported and handed back to practice nurse in GP offices or at home	Yes German	“12 questions were added to the questionnaire to cover topics important to patients in a primary care setting”	Pair-wise deletion Patients excluded if missing data on global question “willingness to stop if the doctor said it was possible”	Items: “I spend a lot of money on my medicines”, “I have had a bad experience when stopping a medicine before”, “I would be reluctant to stop a medicine that I had been taking for a long time” (2.3%)
Alshammari <i>et al.</i> , 2021, Saudi Arabia <sup>28</sup>	138, cross-sectional survey	Hospitalized patients, ≥ 60 years, ≥ 3 chronic diseases, ≥ 5 long-term medications	Interview-based or self-administered questionnaire	Yes Arabic	No	Complete case analysis “24 were not able to complete the questionnaire”	NA
Bucsa <i>et al.</i> , 2022, Romania <sup>29</sup>	219, cross-sectional survey	≥ 65 years, ≥ 1 chronic disease, ≥ 1 long-term medication	NA, Internal medicine departments in university hospital	Yes, Romanian	No	NA	NA
Bužančić <i>et al.</i> , 2021, Croatia <sup>30</sup>	315, cross-sectional survey	≥ 40 years, ≥ 1 long-term medication	Handed out to participants. Completed at home or at community pharmacies, with or without pharmacist assistance	Yes, Croatian	No	NA	NA
Cardwell <i>et al.</i> ,2019, Ireland <sup>31</sup>	200, survey within a non- randomized study	≥ 65 years, ≥ 10 medications	Self-administered with help available, community setting	No	No	NA	Domain “Burden” (19%)



Cardwell et al., 2020, Ireland <sup>32</sup>	96, survey within a non-randomized study	Primary care patients ≥ 65 years, ≥ 10 repeat medicines	NA, General practices	No	No	NA	NA
Cateau et al., 2023, Switzerland <sup>33</sup>	73, cross-sectional survey	Nursing home residents	NA, nursing home	Yes, French	No	NA	NA
de Juan Roldán et al., 2022, Spain <sup>34</sup>	60, cross-cultural adaptation	≥ 18 years ≥ 5 medications (duration ≥ 6 months)	Self-complete, 3 urbans primary care health centers	Yes, Spanish	No	Complete case analysis “Questionnaires with more than 2 blank items would be excluded”	NA
Edelman 2019, Netherlands <sup>35,36</sup>	179, cross-sectional survey	Men ≥ 30 years with lower urinary tract symptoms, taking an alpha-blocker	NA, NA	Yes, Dutch	Yes, Modified questions to create alpha-blocker-specific rPATD factors	NA	NA
Gaurang et al., 2021, India <sup>37</sup>	156, cross-sectional survey	Patients ≥ 18 years with chronic diseases, ≥ 1 regular medication and their caregivers	Interviewer assisted in a tertiary health care facility	Yes, Tamil	No	Complete case analysis “28 questionnaires were incomplete and were excluded from the study”	NA
Gilpin et al. 2022, United Kingdom <sup>38</sup>	150, cross-sectional survey	Hospitalized patients ≥ 65 years, ≥ 1 medication	Completed on the acute admission. Nurse identified appropriate participants. Self-administered, hospital setting	No	No	NA	NA
Gnjidic 2019, Australia <sup>39</sup>	42, survey in a feasibility study	≥ 65 years, taking a benzodiazepine	Self-administered, hospital setting	No	5 benzodiazepine-specific questions were added	NA	NA
Growdon et al. 2022, United-States <sup>40</sup>	422, survey in a cohort study	≥ 65 years with possible or probable dementia	Participants or their proxy respondents undergo annual interviews	No	Yes, “selected prompts were: (1) “You feel that you may be taking one or more medicines that you no	NA	NA

					longer need” (belief about necessity of one's medications); (2) “If your doctor said it was possible, you would be willing to stop one or more of your regular medications” (willingness to deprescribe); and (3) “What is the maximum number of pills you would be comfortable taking daily?””		
Hanna et al. 2023, Lebanese <sup>41</sup>	262, cross-sectional survey	Ambulatory adults ≥ 65 years ≥ 1 chronic medication	Face-to-face interviews	Yes, Arabic	No	NA	NA
Ikeji 2019, USA <sup>42,43</sup>	19, cross-sectional survey	≥ 65 years, taking a PPI	NA, outpatient clinic	No	Modified to focus on proton pump inhibitors	NA	NA
Jungo et al. 2021, Switzerland <sup>44,45</sup>	323, survey within a cluster-RCT	≥ 65 years, ≥ 3 chronic disease, ≥ 5 long-term medications	Baseline phone-call of the RCT	Yes, German	No	NA	NA
Kua 2020, Singapore <sup>46</sup>	615, cross-sectional survey	≥ 65 years, ≥ 1 medication and caregivers	Self-administered, hospitals, community pharmacies and primary care clinics	No	No	NA	NA
Kua 2019, Malaysia <sup>47,48</sup>	502, cross-sectional survey	≥ 60 years, ≥ 1 medication and caregivers	Self-administered, community	Yes, Mandarin and Malay	No	NA	NA

Khasawneh et al. 2022, Jordan <sup>49</sup>	719, cross-sectional survey	Adults with chronic diseases	pharmacies and primary care clinics Online questionnaire, posted to social media portals	Y, Arabic	NA	NA	NA
Lee et al. 2022, South Korea <sup>50</sup>	500, cross-sectional survey	≥ 65 years, ≥ 6 long-term medications	Online survey, e-mail to the panel	Y, Korean	No	NA	NA
Lukacena et al. 2022, United-States <sup>51</sup>	103, cross-sectional survey	≥ 18 years, ≥ 3 chronic medications	NA, At the pharmacies on iPads	N	No	Pair-wise deletion “For the regression analysis, those with missing values on key characteristics were excluded”	NA
Lundby et al. 2021, Denmark <sup>52</sup>	300, cross-sectional survey	Geriatric inpatients, geriatric outpatients, and nursing home residents with Orientation-Memory-Concentration score of ≥8	Researcher-administered, in geriatric wards or nursing homes	Y, Danish	No	Others “Individuals with two or more missing items within the same rPATD factor did not receive a total score.”	Item: “I feel that I may be taking one or more medicines that I no longer need” (5%)
Lundby 2020, Denmark <sup>53,54</sup>	162, validation study and cross-sectional survey	Nursing home residents with Orientation-Memory-Concentration score of ≥8	Researcher - administered, in nursing homes	Yes, Danish	No	Others “If two or more items were missing within a given rPATD factor, the factor was discarded for that patient, that is, no total score was calculated for the factor.”	Item: “I spend a lot of money on my medicines” (7%)
Major 2019, Australia <sup>55</sup>	66, cross-sectional survey within an intervention study	Average 12 medications	Self-administered, during pharmacist home visit	No	Q7 ?	NA	NA
Martinez 2020, USA <sup>56</sup>	30, pre-post intervention study	Women ≥ 45 years, insomnia symptoms	Self-administered, community setting	No	No	Complete case analysis “Only participants who completed all components	NA

		and sleep aids usage ≥ 3 months					of the rPATD at baseline and post-intervention were included in this analysis.”	
McCarthy et al. 2022, Ireland <sup>57</sup>	229, survey within a cluster-RCT	≥65 years and prescribed ≥15 repeat medicines	Postal questionnaires, at home	No	No		NA	NA
Navid et al. 2021, United-States <sup>58</sup>	134, retrospective cohort study.	Heart failure with preserved ejection fraction	First clinical encounter in the program	No	No		Complete case analysis “Given low degree of missingness, we conducted a complete case analysis”	NA
Ng 2019, Malaysia <sup>59</sup>	18, cross-sectional survey	≥ 18 years diagnosed with Parkinson disease	NA, at a public health talk	NA	NA		NA	NA
Nusair 2020, Jordany <sup>60</sup>	358, validation study and survey	≥ 18 years, ≥ 5 medications	NA, NA	Yes, Arabic	No		NA	NA
Nusair et al. 2022, Jordan <sup>61</sup>	501, cross-sectional survey	≥18 years, ≥ 5 medications, and do not require a caregiver or assistance at home	Interviewed by a clinical pharmacist	Yes, Arabic	No		NA	NA
Oktora et al. 2023, Indonesia <sup>62</sup>	196, cross-sectional survey	≥60 years with type 2 diabetes	Research assistants, in primary care centers	Yes, Indonesian	Yes, “name of the specific medicines prescribed”		“Complete case analyses were performed”	NA
Omar 2019, Malaysia <sup>63</sup>	189, cross-sectional survey	≥ 65 years, ≥ 1 medication	NA, NA	Yes, Malay	No		Complete case analysis “Those who did not complete the questionnaire were excluded from the study.”	NA
Paque 2019, Belgium <sup>64</sup>	296, cross-sectional survey	≥ 65 years with limited life-expectancy and caregivers	Researcher-administered, in nursing home	Yes, Dutch	Yes, addition of an item on patients’ willingness to speak to their general practitioner		NA	NA

Pereira et al. 2020, Portugal <sup>65</sup>	25, cross-sectional survey	≥ 65 years taking at least 1 medication	NA	Yes, Portuguese	about their medications No	NA	NA
Pereira et al. 2022, Portugal <sup>66-69</sup>	192, cross-cultural adaptation and cross-sectional survey	≥ 65 years and taking at least 1 regular medication	Self-administered or “interview administered by the researcher to some of the participants upon solicitation”	Yes, Portuguese	No	Pair-wise deletion “Missing values were deleted pairwise”	Items: “I feel that I am taking a large number of medicines”, “I spend a lot of money on my medicines”, “I would like to try stopping one of my medicines to see how I feel without it”, and “I have had a bad experience when stopping a medicine before” (1.6%) Item: “I spend a lot of money on my medicines” (8%)
Rakheja et al. 2022, Canada <sup>70</sup>	110, cross-sectional survey	≥ 65 years and ≥ 1 prescribed medication for the past 3 months	Self-administered, in community pharmacies and centers	Yes, French	No	NA	
Reeve 2018, Australia <sup>71</sup>	21, development and pilot study	≥ 18 years, ≥ 1 medication, with a diagnosis of mild cognitive impairment or dementia	Researcher-administered, NA	No	Yes, rPATDcog	Others “Returned questionnaires (by mail or submitted online) had to have at least 50% of the questions completed to be included in the analysis”	
Reeve 2019, Australia <sup>72,73</sup>	386, validation study cross-sectional survey	≥ 65 years, ≥ 1 medication, and caregivers	Self-administered, at home	No	No	Others “Exclusion from analysis (<50% of questions answered)”	Domain “Burden” (12.4%)
Reeve 2018, United-States <sup>74</sup>	1981, cross-sectional survey	≥ 65 years	Self-administered, at home	No	Yes, 8 items from rPATD and 2 items from PATD, and 4-point Likert-scale	NA	NA

Reeve et al. 2023, United-States <sup>75</sup> Maiyani et al. 2022, United-States <sup>76</sup>	553, survey within a cluster-RCT	≥ 65 years, Alzheimer disease and related dementias or mild cognitive impairment, ≥ 1 additional chronic condition, ≥ 5 long-term medications	Self-administered or with help of a caregiver, at home	No	(deleted “unsure”) Yes, rPATDcog	Complete case analysis “Missing data were excluded from analysis”	Items: “I feel that I may be taking one or more medicines that I no longer need” and “Overall, I am satisfied with my current medicines” (1.1%)
Roux et al. 2022, France <sup>77</sup>	367, Cross-sectional survey	Community-dwelling or nursing home older adults ≥ 65 years taking ≥ 1 prescribed medications	Administered by researchers or healthcare professionals , NA	Yes, French	No	Complete case analysis Score for “Individuals without missing data for all the questions in the corresponding factor”	Domain “Burden” (6.8%)
Roux et al. 2021, France <sup>78</sup>	320, Cross-cultural adaptation	≥ 65 years ≥ 1 chronic medication (i.e. use ≥ 3 months) and lived in the community or in institutions	Self-administered with a researcher present, NA	Yes, French	No	Complete case analysis “Questionnaires with at least one missing data were excluded from analyses.”	NA
Saka et al. 2022, Nigeria <sup>79</sup>	350, Cross-sectional survey	Ambulatory patients ≥ 65 years, ≥ 5 chronic medications	Interviewer-administration, Medical outpatient units of two secondary healthcare facilities	Yes, Yoruba	No	Complete case analysis “Nine copies (2.3%) were excluded due to missing data”	NA
Scott 2019, United-Kingdom <sup>20</sup>	75, cross-sectional survey	≥ 70 years, ≥ 5 medications and caregivers	Self-administered with help available, at hospital	No	Yes, change in 1 item from the “Burden” domain regarding cost of medicines	NA	NA
Serrano Giménez et al. 2020, Spain <sup>80</sup>	42, survey within a cohort study	Patient living with HIV on highly active antiretroviral therapy ≥ 65 years	Self-reported, follow-up by the Pharmaceutical Care Consultation	Yes, Spanish	No	NA	NA

Shrestha et al. 2021, Australia <sup>81</sup>	385, Cross-sectional survey	Ambulatory patients $\geq 65$ years, $\geq 1$ regular medication	of Viral Diseases from the Hospital Pharmacy Service. Face-to-face interview, hospitals	Yes, Nepali	No	NA	NA
Tan et al. 2022, China <sup>82</sup>	1897, Cross-sectional survey	Residents $\geq 65$ years	Face-to-face interviews, community health centers	Yes, Chinese	No	Complete case analysis “We excluded participants with any missing item of the rPATD questionnaire”	NA
Tegegn 2018, Ethiopia <sup>83</sup>	316, cross-sectional survey	$\geq 65$ years, $\geq 1$ medication	Researcher-administered	Yes, Amharic	Yes, 4-point Likert-scale (deleted “unsure”)	NA	NA

\*reported in the text or based on table of results.

GP: general practitioner; HIV: human immunodeficiency virus; NA: not available; RCT: randomized controlled trial

**Table 2.** Scores of the rPATD domains using “complete domain analysis”, “personal mean score imputation” and “multiple imputation” methods on the DeprescriPP dataset (n=1151)

<b>Methods of handling missing data</b>	<b>Cases n (%)</b>	<b>rPATD domain mean score</b>	<b>Standard deviation</b>
<b>Complete domain analysis</b>			
Burden	942 (81.8)	2.51	1.06
Appropriateness	952 (82.7)	3.87	0.97
Concerns about stopping	919 (79.8)	2.89	0.95
Involvement	978 (85.0)	4.36	0.67
<b>Personal mean score imputation</b>			
Burden	1067 (92.7)	2.54	1.06
Appropriateness	1062 (92.3)	3.86	0.99
Concerns about stopping	1027 (89.2)	2.90	0.95
Involvement	1046 (90.9)	4.34	0.69
<b>Multiple imputation</b>			
Burden	1113 (96.7)	2.56	1.09
Appropriateness	1105 (96.0)	3.83	1.01
Concerns about stopping	1059 (92.0)	2.93	0.99
Involvement	1067 (92.7)	4.34	0.71



**Table 3.** Association of “If my doctor said it was possible, I would be willing to stop one or more of my regular medicines” response\* with the four rPATD domains using three different methods on the DeprescriPP dataset.

Methods of handling missing data	Crude odds ratio [95% confidence interval]	p-value
<b>Complete case analysis</b>		
Burden	1.02 [0.83-1.26]	0.847
Appropriateness	0.55 [0.43-0.72]	<b>0.000</b>
Concerns about stopping	0.47 [0.38-0.59]	<b>0.000</b>
Involvement	1.95 [1.49-2.54]	<b>0.000</b>
<b>Personal mean score imputation</b>		
Burden	0.99 [0.82-1.19]	0.890
Appropriateness	0.54 [0.44-0.67]	<b>0.000</b>
Concerns about stopping	0.49 [0.41-0.59]	<b>0.000</b>
Involvement	1.83 [1.46-2.28]	<b>0.000</b>
<b>Multiple imputation</b>		
Burden	0.99 [0.83-1.19]	0.936
Appropriateness	0.53 [0.43-0.66]	<b>0.000</b>
Concerns about stopping	0.50 [0.42-0.60]	<b>0.000</b>
Involvement	1.86 [1.50-2.33]	<b>0.000</b>

\* “If my doctor said it was possible, I would be willing to stop one or more of my regular medicines” was coded 0 (unsure, disagree, strongly disagree) or 1 (agree, strongly agree).

**Table 4.** Association of “I would like to try stopping one of my medicines to see how I feel without it” response\* with the four rPATD domains using three different methods on the DeprescrIPP dataset

Methods of handling missing data	Crude odds ratio [95% confidence interval]	p-value
<b>Complete case analysis</b>		
Burden	1.71 [1.26-2.33]	<b>0.001</b>
Appropriateness	14.7 [9.50-22.90]	<b>0.000</b>
Concerns about stopping	2.02 [1.49-2.73]	<b>0.000</b>
Involvement	0.47 [0.32-0.69]	<b>0.000</b>
<b>Personal mean score imputation</b>		
Burden	1.53 [1.17-2.00]	<b>0.002</b>
Appropriateness	14.90 [10.16-21.85]	<b>0.000</b>
Concerns about stopping	1.83 [1.41-2.36]	<b>0.000</b>
Involvement	0.49 [0.35-0.69]	<b>0.000</b>
<b>Multiple imputation</b>		
Burden	1.46 [1.13-1.90]	<b>0.004</b>
Appropriateness	15.43 [10.61-22.43]	<b>0.000</b>
Concerns about stopping	1.73 [1.35-2.21]	<b>0.000</b>
Involvement	0.50 [0.36-0.70]	<b>0.000</b>

\* “I would like to try stopping one of my medicines to see how I feel without it” was coded 0 (disagree, strongly disagree) or 1 (unsure, agree, strongly agree).

**Table 5.** Scores of the rPATD domains using “complete domain analysis”, “personal mean score imputation” and “multiple imputation” methods on the on the LESS dataset (n=306)

<b>Methods of handling missing data</b>	<b>Cases n (%)</b>	<b>Mean score</b>	<b>Standard deviation</b>
<b>Complete domain analysis</b>			
Burden	292 (95.4)	2.55	1.00
Appropriateness	297 (97.1)	3.76	0.92
Concerns about stopping	289 (94.4)	2.37	0.83
Involvement	294 (96.1)	4.61	0.51
<b>Personal mean score imputation</b>			
Burden	303 (99.0)	2.55	1.00
Appropriateness	304 (99.3)	3.75	0.93
Concerns about stopping	303 (99.0)	2.40	0.87
Involvement	305 (99.7)	4.60	0.51
<b>Multiple imputation</b>			
Burden	306 (100.0)	2.55	1.00
Appropriateness	305 (99.7)	3.75	0.93
Concerns about stopping	306 (100.0)	2.40	0.87
Involvement	306 (100.0)	4.60	0.51

**Table 6.** Association of “If my doctor said it was possible, I would be willing to stop one or more of my regular medicines” response\* with the four rPATD domains using three different methods on the LESS dataset

Methods of handling missing data	Crude odds ratio [95% confidence interval]	p-value
<b>Complete case analysis</b>		
Burden	1.05 [0.69-1.60]	0.826
Appropriateness	0.60 [0.37-0.97]	<b>0.036</b>
Concerns about stopping	0.45 [0.31-0.66]	<b>0.000</b>
Involvement	1.41 [0.75-2.64]	0.290
<b>Personal mean score imputation</b>		
Burden	1.07 [0.72-1.60]	0.729
Appropriateness	0.59 [0.37-0.93]	<b>0.023</b>
Concerns about stopping	0.44 [0.31-0.63]	<b>0.000</b>
Involvement	1.40 [0.79-2.51]	0.252
<b>Multiple imputation</b>		
Burden	1.03 [0.70-1.53]	0.864
Appropriateness	0.56 [0.36-0.89]	<b>0.013</b>
Concerns about stopping	0.45 [0.32-0.64]	<b>0.000</b>
Involvement	1.40 [0.78-2.50]	0.255

\* “If my doctor said it was possible, I would be willing to stop one or more of my regular medicines” was coded 0 (unsure, disagree, strongly disagree) or 1 (agree, strongly agree).

**Table 7.** Association of “I would like to try stopping one of my medicines to see how I feel without it” response\* with the four rPATD domains using three different methods on the LESS dataset

Methods of handling missing data	Crude odds ratio [95% confidence interval]	p-value
<b>Complete case analysis</b>		
Burden	1.68 [1.01-2.79]	<b>0.044</b>
Appropriateness	24.8 [10.73-57.17]	<b>0.000</b>
Concerns about stopping	1.54 [0.95-2.49]	0.080
Involvement	0.37 [0.17-0.79]	<b>0.011</b>
<b>Personal mean score imputation</b>		
Burden	1.59 [0.99-2.57]	0.057
Appropriateness	23.91 [10.79-53.00]	<b>0.000</b>
Concerns about stopping	1.49 [0.96-2.29]	0.074
Involvement	0.38 [0.19-0.76]	<b>0.006</b>
<b>Multiple imputation</b>		
Burden	1.63 [1.03-2.59]	<b>0.038</b>
Appropriateness	24.15 [11.11-52.52]	<b>0.000</b>
Concerns about stopping	1.52 [0.99-2.33]	0.053
Involvement	0.39 [0.19-0.78]	<b>0.008</b>

\* “I would like to try stopping one of my medicines to see how I feel without it” was coded 0 (disagree, strongly disagree) or 1 (unsure, agree, strongly agree).